Our latest articles
FDA scrutiny now hits Parp inhibitors
A November adcom could decide whether Zejula will lose yet more ground to Lynparza.
Fourth-quarter data for the little guys
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Go or no go? GSK takes its turn with a novel anaemia class
Amicus and Astrazeneca have notable approaching Pdufa decisions, while a panel for GSK’s daprodustat could change the course of a controversial drug class.
Ember burns bright for Angle
A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.
Lecanemab can; now the wait for details begins
Eisai is rewarded for doubling down on lecanemab with an apparent win that endorses 20 years of research.
Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Pepgen aims to overtake Sarepta
Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.
Big pharma’s key fourth-quarter data
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
Ocular Therapeutix joins the long-acting race
But the group has a long way to go to set up a showdown with Eylea.
PCSK9 pipeline shows signs of saturation
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
